Rofecoxib was withdrawn due to:
**Core Concept**
The question tests the student's knowledge of **adverse drug reactions**, specifically those related to **nonsteroidal anti-inflammatory drugs (NSAIDs)** and **cyclooxygenase-2 (COX-2) inhibitors**. Rofecoxib is a well-known COX-2 inhibitor.
**Why the Correct Answer is Right**
Rofecoxib was withdrawn from the market due to its association with an increased risk of **cardiovascular events**, such as myocardial infarction and stroke. This is thought to be related to the drug's mechanism of action, which involves the selective inhibition of **COX-2**, leading to an imbalance in the production of **prostacyclin** and **thromboxane A2**.
**Why Each Wrong Option is Incorrect**
**Option A:** Not specified, but potential incorrect options might include hepatic toxicity or gastrointestinal bleeding, which are common adverse effects of NSAIDs but not the primary reason for rofecoxib's withdrawal.
**Option B:** Similarly, not specified, but could include other potential side effects that are not the main reason for its withdrawal.
**Option C:** Again, not specified, but could be another incorrect option.
**Option D:** Not the correct answer, as the question is about the reason for rofecoxib's withdrawal.
**Clinical Pearl / High-Yield Fact**
It's essential to remember that **COX-2 inhibitors** can increase the risk of **cardiovascular events**, and this knowledge can help guide treatment decisions and patient counseling.
**Correct Answer:** D. Increased risk of cardiovascular events.